This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Pulmonary disease				
Pulmonary fibrosis	Chemokine CXC motif ligand 10 (CXCL10; IP-10); syndecan 4 (SDC4); CXC chemokine receptor 3 (CXCR3)	<i>In vitro</i> and mouse studies suggest that a modified version of CXCL10 could be used to treat pulmonary fibrosis. In a migration assay using fibroblasts from patients with pulmonary fibrosis, CXCL10 modified to lack CXCR3-binding activity significantly inhibited fibroblast migration compared with no treatment ($p < 0.01$). In a mouse model of lung injury, modified Cxcl10 inhibited fibrosis in wild-type mice but not in mice lacking the Cxcl10 signal transfer molecule Sdc4. Next steps could include testing the antifibrotic effects of modified CXCL10 in other models of fibrosis.	Patent and licensing status unavailable	Jiang, D. <i>et al.</i> <i>J. Clin. Invest.</i> ; published online May 17, 2010; doi:10.1172/JCI38644 Contact: Paul W. Noble, Duke University School of Medicine, Durham, N.C. e-mail: paul.noble@duke.edu Contact: Dianhua Jiang, same affiliation as above e-mail: dianhua.jiang@duke.edu
		SciBX 3(22); doi:10.1038/scibx.2010.682 Published online June 3, 2010		